Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,068 across all filing types
Latest filing 2022-05-25 AGM Information
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Report from Annual General Meeting in Vivesto AB
AGM Information Classification · 100% confidence The document is explicitly titled "Report from Annual General Meeting in Vivesto AB" and details the resolutions passed at the meeting held on May 25, 2022. It covers key AGM items such as adoption of financial statements, dividend resolution, election of the Board and auditor, approval of remuneration report, and authorization for share/warrant/convertible issues. This content directly corresponds to the definition of AGM Information.
2022-05-25 English
Kommuniké från årsstämma i Vivesto AB
AGM Information Classification · 99% confidence The document is titled "Kommuniké från årsstämma i Vivesto AB" (Communiqué from the Annual General Meeting in Vivesto AB) and details the resolutions passed at the AGM held on May 25, 2022. Key decisions mentioned include the approval of financial statements, decisions on profit distribution (no dividend), election of the board and auditor, approval of remuneration reports, and authorization for share issuance and long-term incentive programs (stock options). These contents are characteristic of the official minutes or a summary of decisions made at an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2022-05-25 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vivesto AB for the period January 1 to March 31, 2022. It contains comprehensive financial data, including net sales, operating results, and earnings per share, as well as detailed management commentary on business operations, R&D progress, and future outlook. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-05-25 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim report for the period January 1, 2022 – March 31, 2022'. It contains comprehensive financial data, including consolidated net sales, operating profit/loss, net profit/loss, and earnings per share for the specified quarter. It also includes a CEO review, business updates, and strategic outlook, which are standard components of a quarterly financial report. It is not an announcement of a report, but the report itself. Q1 2022
2022-05-25 English
Nytt antal aktier och röster i Vivesto
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement dated April 29, 2022, titled "Nytt antal aktier och röster i Vivesto" (New number of shares and votes in Vivesto). It explicitly states that the number of shares and votes has increased due to a rights issue registration. It details the new total number of shares (538,043,455) and the resulting capital change. Crucially, it ends with a statement that this information is required to be made public under financial instrument trading laws and includes a link to a PDF attachment. Because the document itself is an announcement detailing a change in capital structure (share count) and is very short, it fits the description of a Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Since the core subject is the change in the total number of shares following a rights issue, the most specific category is Capital/Financing Update (CAP). It is not a Report Publication Announcement (RPA) because it is reporting the event itself, not just announcing the publication of a separate, larger report.
2022-04-29 Swedish
New number of shares and votes in Vivesto
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document announces a change in the total number of shares and votes in Vivesto AB following a preferential rights issue registration. It explicitly states the increase in shares and share capital. This type of announcement, detailing changes to the total outstanding shares, directly relates to the company's capital structure. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a financing update (CAP) which usually relates to the *raising* of funds rather than the administrative update post-issuance.
2022-04-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.